释 义 n. 奥斯替尼，阿斯利康非小细胞肺癌新药名
例 句 Osimertinib is an effective third-generation tyrosine kinase inhibitor (TKI) for EGFR-mutant lung cancers. 奥斯替尼是治疗EGFR型肺癌的有效的第三代酪氨酸激酶抑制剂（TKI）。
作者： Morana Vojnic
期刊：J Thorac Oncol
Long-term clinical benefits of EGFR tyrosine kinase inhibitors (EGFR TKIs) in EGFR-mutant NSCLCs remain limited by the development of drug resistance. The most common mechanism of resistance to first- and second-generation EGFR TKIs, the EGFR T790M mutation (which accounts for 60% of cases), can be targeted successfully with third-generation drugs such as osimertinib. Recently, osimertinib has been approved as first-line therapy for EGFR-mutant lung cancer. As expected, disease progression due to acquired resistance to osimertinib has emerged, with the most common alteration described to date being the EGFR C797S mutation. Activation of parallel signaling pathways (amplification of erb-b2 receptor tyrosine kinase 2 gene [HER2] and gene MNNG HOS Transforming gene [MET]) or downstream signaling (mutations in KRAS, phospha-tidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene [PIK3CA], and BRAF) has also been shown to induce resistance to osimertinib and other EGFR TKIs. Several acquired gene rearrangements, including fusions involving ALK receptor tyrosine kinase gene (ALK), BRAF, fibroblast growth factor receptor 3 gene (FGFR3), neurotrophic receptor tyrosine kinase 1 gene (NTRK1), and ret proto-oncogene gene (RET), have recently been reported as possible mechanisms of resistance to EGFR TKI therapy.